CMS Schedules November Meeting to Discuss Provenge Coverage

Drug Industry Daily
A A
As the Medicare debate over Dendreon’s Provenge continues, the Centers for Medicare & Medicaid Services (CMS) is convening a meeting to consider the evidence for coverage of the prostate cancer drug.

To View This Article:

Login

Subscribe To Drug Industry Daily